Tirzepatide Reduces Alcohol Drinking and Relapse in Rodents Through Brain Reward Circuits
Tirzepatide attenuated alcohol reward, reduced voluntary drinking, prevented binge and relapse-like behaviors, and induced lasting changes in lateral septum signaling in rodents.
Quick Facts
What This Study Found
Tirzepatide attenuated alcohol reward (dopamine release p<0.001), dose-dependently reduced intake (p<0.001), prevented binge (p<0.01) and relapse drinking (p<0.001), with sustained efficacy, and induced lasting synaptic depression and histone changes in the lateral septum.
Key Numbers
How They Did This
Comprehensive rodent behavioral battery (locomotor activity, CPP, two-bottle choice, drinking in the dark, alcohol deprivation effect), microdialysis, electrophysiology, and proteomics in the lateral septum.
Why This Research Matters
This is the most comprehensive preclinical study of a GLP-1/GIP agonist for alcohol use disorder, providing both behavioral and mechanistic evidence that could support human clinical trials.
The Bigger Picture
Tirzepatide is already FDA-approved for diabetes and obesity. These findings position it for potential repurposing for alcohol use disorder, with the advantage of simultaneously addressing metabolic complications of heavy drinking.
What This Study Doesn't Tell Us
Rodent models; alcohol consumption patterns differ from human AUD. Lateral septum mechanisms need human validation. Cannot determine relative contributions of GLP-1R vs GIPR agonism.
Questions This Raises
- ?Will tirzepatide reduce alcohol consumption in human clinical trials?
- ?Is the lateral septum the primary brain target, or do other regions contribute?
- ?Does GIP receptor agonism add benefit over GLP-1 alone for AUD?
Trust & Context
- Key Stat:
- Blocked relapse (p<0.001) Tirzepatide prevented relapse-like drinking after alcohol deprivation and maintained efficacy during repeated dosing
- Evidence Grade:
- Comprehensive preclinical study with behavioral, neurochemical, electrophysiological, and proteomic evidence. Strong preclinical case for human trials.
- Study Age:
- Published in 2025.
- Original Title:
- Tirzepatide reduces alcohol drinking and relapse-like behaviours in rodents.
- Published In:
- EBioMedicine, 124, 106119 (2026)
- Authors:
- Edvardsson, Christian E(6), Adermark, Louise, Gottlieb, Sam, Alfreji, Safana, Emous, Thaynnam A, Gouda, Yomna, Thorsell, Annika, Vujičić, Milica, Aranäs, Cajsa, Benrick, Anna, Wernstedt Asterholm, Ingrid, Lopez, Marcelo F, Becker, Howard C, Jerlhag, Elisabet
- Database ID:
- RPEP-15136
Evidence Hierarchy
Frequently Asked Questions
Could tirzepatide help people stop drinking?
In this thorough rodent study, tirzepatide reduced alcohol's rewarding effects, cut drinking, prevented binge drinking, and blocked relapse. These results strongly support testing in human clinical trials for alcohol use disorder.
How does an obesity drug reduce alcohol drinking?
Tirzepatide activates GLP-1 and GIP receptors in brain reward circuits, reducing the pleasurable dopamine release from alcohol. It also changed nerve signaling in the lateral septum — a brain region that controls reward-seeking behavior.
Read More on RethinkPeptides
Related articles coming soon.
Cite This Study
https://rethinkpeptides.com/research/RPEP-15136APA
Edvardsson, Christian E; Adermark, Louise; Gottlieb, Sam; Alfreji, Safana; Emous, Thaynnam A; Gouda, Yomna; Thorsell, Annika; Vujičić, Milica; Aranäs, Cajsa; Benrick, Anna; Wernstedt Asterholm, Ingrid; Lopez, Marcelo F; Becker, Howard C; Jerlhag, Elisabet. (2026). Tirzepatide reduces alcohol drinking and relapse-like behaviours in rodents.. EBioMedicine, 124, 106119. https://doi.org/10.1016/j.ebiom.2025.106119
MLA
Edvardsson, Christian E, et al. "Tirzepatide reduces alcohol drinking and relapse-like behaviours in rodents.." EBioMedicine, 2026. https://doi.org/10.1016/j.ebiom.2025.106119
RethinkPeptides
RethinkPeptides Research Database. "Tirzepatide reduces alcohol drinking and relapse-like behavi..." RPEP-15136. Retrieved from https://rethinkpeptides.com/research/edvardsson-2026-tirzepatide-reduces-alcohol-drinking
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.